Speaking of Urology podcast: Dr. Angela Smith discusses Jelmyto for low-grade UTUC

In this episode, Angela B. Smith, MD, MS, of UNC Lineberger Comprehensive Cancer Center, discusses the recent FDA approval of Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer.

Related Videos

Related Content

Advertisement

January 15th 2025

New Drug Application initiated with FDA for TAR-200 for NMIBC

Hannah Clarke Benjamin P. Saylor Kyle Doherty

The NDA is supported by data from cohort 2 of the phase 2b SunRISe-1 trial.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

January 11th 2025

The economics of bladder cancer in the US: Increasing costs and unsustainable patterns

Michael S. Cookson, MD, MMHC

"The increasing expenses associated with bladder cancer treatment highlight wider issues regarding the sustainability of health care expenditures in the US," writes Michael S. Cookson, MD, MMHC, FACS.

September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff

In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.

January 10th 2025

FDA greenlights phase 2 SURF302 trial of TYRA-300 in NMIBC

Hannah Clarke

"We expect to initiate patient dosing in the second quarter of this year, with initial three-month [complete response] data to follow," says Doug Warner.

January 9th 2025

9MW2821/toripalimab awarded breakthrough therapy designation in China for mUC

Hannah Clarke

9MW2821 was previously awarded a breakthrough therapy designation as a monotherapy for locally advanced or metastatic urothelial carcinoma.

Related Content

Advertisement

January 15th 2025

New Drug Application initiated with FDA for TAR-200 for NMIBC

Hannah Clarke Benjamin P. Saylor Kyle Doherty

The NDA is supported by data from cohort 2 of the phase 2b SunRISe-1 trial.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

January 11th 2025

The economics of bladder cancer in the US: Increasing costs and unsustainable patterns

Michael S. Cookson, MD, MMHC

"The increasing expenses associated with bladder cancer treatment highlight wider issues regarding the sustainability of health care expenditures in the US," writes Michael S. Cookson, MD, MMHC, FACS.

September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff

In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.

January 10th 2025

FDA greenlights phase 2 SURF302 trial of TYRA-300 in NMIBC

Hannah Clarke

"We expect to initiate patient dosing in the second quarter of this year, with initial three-month [complete response] data to follow," says Doug Warner.

January 9th 2025

9MW2821/toripalimab awarded breakthrough therapy designation in China for mUC

Hannah Clarke

9MW2821 was previously awarded a breakthrough therapy designation as a monotherapy for locally advanced or metastatic urothelial carcinoma.